Accès ouvert · CC BY

A perspective on Oxford’s R21/Matrix-M™ malaria vaccine and the future of global eradication efforts

Article scientifique 2024 Sciences de la santé Anglais

Résumé

Abstract Malaria affects millions of lives annually, particularly in tropical and subtropical regions. Despite being largely preventable, 2021 witnessed 247 million infections and over 600,000 deaths across 85 countries. In the ongoing battle against malaria, a promising development has emerged with the endorsement by the World Health Organization (WHO) of the R21/Matrix-M™ Malaria Vaccine. Developed through a collaboration between the University of Oxford and Novavax, this vaccine has demonstrated remarkable efficacy, reaching 77% effectiveness in Phase 2 clinical trials. It is designed to be low-dose, cost-effective, and accessible, with approval for use in children under three years old. This perspective paper critically examines the R21/Matrix-M malaria vaccine, its development, potential impact on global malaria eradication efforts, and the challenges and opportunities it presents.

Citer ce document

Aderinto, N., Olatunji, G. D., Kokori, E., Sikirullahi, S., Aboje, J. E., & Ojabo, R. E. (2024). A perspective on Oxford’s R21/Matrix-M™ malaria vaccine and the future of global eradication efforts. Malaria Journal. https://doi.org/10.1186/s12936-024-04846-w

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 27/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 12

Téléchargements (hors robots) : 0

Méthode de comptage